News & Updates

Show Multimedia Only

The unseen comorbidity of diabetes

23 Jun 2023 by

Diabetes is the most prevalent cause of blindness in working-age individuals. However, 64 percent of Malaysians are not aware that diabetes can lead to eye problems. On the other hand, heart disease, kidney disease, and amputations are some of the health issues that come to mind when diabetes is mentioned.

23 Jun 2023

Low-dose atropine helps control childhood myopia progression

18 Jun 2023

The novel, preservative-free, low-dose atropine formulation NVK002 appears to be beneficial in the treatment of myopia progression in children when compared with placebo, according to the results of a phase III study.

18 Jun 2023

OPT-302 2.0 mg plus ranibizumab leads to superior vision gains in nAMD

05 Jun 2023 by

Treatment with 2.0-mg OPT-302, a biologic inhibitor of vascular endothelial growth factor (VEGF)-C and D, in combination with ranibizumab, an anti‒VEGF-A inhibitor, results in greater vision gains when compared with the current standard of care for neovascular age-related macular degeneration (nAMD), reports a study. In addition, the combined therapy has an acceptable safety profile.

05 Jun 2023

Dietary modification ups glaucoma risk in women

04 Jun 2023

Dietary modification (DM) among individuals in the lowest quartile for percentage calories from total fat at baseline is associated with a higher risk of incident primary open-angle glaucoma (POAG) among women, irrespective of age or race, suggests a recent study.

04 Jun 2023

Original New Drug Application Approvals by US FDA (16-31 May 2023)

01 Jun 2023

New drug applications approved by US FDA as of 16-31 May 2023 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

01 Jun 2023

Serum ADMA levels linked to circadian BP variability in glaucoma

27 May 2023

Serum levels of asymmetric dimethylarginine (ADMA) seem to play a major role in the disturbance of circadian blood pressure (BP) variability in patients with glaucoma, suggests a recent study.

27 May 2023

AI raises the bar for diagnosing severe TED

23 May 2023 by

Artificial intelligence (AI) can help diagnose thyroid eye disease (TED) and assess for severity by analysing CT scans, reports an expert at ARVO 2023.

23 May 2023

3-week azithromycin on par with 6-week doxycycline for treating MGD

22 May 2023

In the treatment of moderate-to-severe meibomian gland dysfunction (MGD), a 3-week course of oral azithromycin leads to outcomes that are similar to that achieved with a 6-week course of oral doxycycline, according to a study.

22 May 2023

Delayed capsulotomy much preferable over early procedure to prevent AEs

18 May 2023

Ocular hypertension (OHT) and macular edema (ME) are the most common and relevant adverse events (AEs) following neodymium:yttrium-aluminum-garnet posterior capsulotomy (Nd:YAG-caps), reports a study. These AEs normally occur within 3 months after the procedure, which stresses the need for a close follow-up during this period or a delayed capsulotomy.

18 May 2023

Original New Drug Application Approvals by US FDA (01-15 May 2023)

16 May 2023

New drug applications approved by US FDA as of 01-15 May 2023 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.